| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Departments of Physiology (T.T., Y.A., S.S., P.L.B.) and Medicine (D.J.D., P.L.B.) and Banting and Best Diabetes Centre (D.J.D.), University of Toronto, Toronto, Ontario, Canada M5S 1A8; and Ottawa Health Research Institute (Y.A.), Ottawa, Ontario, Canada K1Y 4E9
Address all correspondence and requests for reprints to: Dr. Patricia L. Brubaker, Room 3366, Medical Sciences Building, University of Toronto, 1 King’s College Circle, Toronto, Ontario, Canada M5S 1A8. E-mail: p.brubaker{at}utoronto.ca.
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
GLP-1 is cosecreted from the intestinal L cell with another hormone, peptide YY1–36 (14, 15, 16, 17), in response to ingested nutrients (18, 19, 20, 21). Once in the circulation, both of these peptides are rapidly degraded by the ubiquitous enzyme, dipeptidyl-peptidase-IV, to form GLP-19–36NH2 and peptide YY3–36NH2 (PYY3–36NH2), respectively (22, 23). Although the GLP-1 fragment GLP-19–36NH2 is not a potent GLP-1 receptor agonist (24), the truncated form of PYY remains biologically active because it inhibits FI when administered to rodents or humans (25, 26, 27, 28, 29, 30). Thus, PYY3–36NH2 has also been proposed as a potential therapeutic agent for the treatment of obesity (31).
Intracerebroventricular administration of GLP-1, Ex4 or PYY3–36NH2 to rodents has been shown to modulate ingestive behavior through binding of the GLP-1R and the neuropeptide Y (NPY) Y2-receptor (Y2-R), respectively (25, 32). Both of these receptors are found in the hypothalamic arcuate nucleus, which has been implicated in the regulation of appetite, as well as in the dorsal vagal complex, nucleus tractus solitarus (NTS), and area postrema (AP) (33, 34). However, these receptors are also expressed in the nodose ganglion of the vagus nerve (35, 36). Because GLP-1, Ex4, and PYY3–36NH2 are all known to cross the blood-brain barrier (BBB) (37, 38, 39), it remains unclear as to how these peptides exert their anorexigenic effects when administered into the peripheral circulation. It is also unknown whether GLP-1 and PYY3–36NH2 interact to decrease FI, as recently found for several peripheral satiety factors including cholecystokinin (CCK), leptin, and amylin (40, 41). Therefore the present study was conducted to address the possible synergistic effects and mechanisms of action of peripherally administered Ex4 and PYY3–36NH2 to suppress FI.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Ex4, human PYY3–36NH2, and exendin-49–39 [Ex49–39] were purchased from Bachem Inc. (Torrance, CA). (S)-N2-[[1-[2-[4-[(R,S)-5,11-dihydro-6(6h)-oxodibenz[b,e]azepin-11-yl]-1-piperazinyl]-2-oxoethyl]-cylopentyl] acetyl]-N-[2-[1,2-dihydro-3,5(4H)-dioxo-1,2-diphenyl-3H-1,2,4-triazol-4-yl]ethyl]-argininamid (BIIE0246) was obtained from Tocris (Ellisville, MO), and capsaicin (8-methyl-N-vanillyl-6-nonenamide), Tween 20, and dimethyl sulfoxide (DMSO, 99.9%) were from Sigma-Aldrich Canada (Oakville, Ontario, Canada).
Feeding studies
For acute studies, mice were fasted in separate cages for 16–18 h with free access to water. On the experimental day, animals were transferred to cages without bedding and injected ip at t = 0 h with 100 µl of either vehicle (saline), Ex4 (0.03, 0.06, 0.3, 3 µg), or PYY3–36NH2 (0.03, 0.06, 0.3, 3 µg) for the individual dose responses. To examine the combined effect of these peptides, mice were treated with 100 µl of either saline, Ex4 (0.06 µg), or PYY3–36NH2 (3 µg) alone or in combination. Immediately thereafter, preweighed Purina Rat Chow was placed in a Petri dish within the cage, and FI was determined at 1, 2, 4, 8, and 24 h by measuring the difference between the preweighed chow and the weight of chow plus spill remaining at the end of each time interval. Animals were tested on a maximum of two occasions, separated by a minimum 3-d wash-out period.
Mice were anesthetized with isoflurane and sc administered 100 µl of either vehicle (10% ethanol, 10% Tween 20, 80% saline) or capsaicin (50 mg/kg) (40), followed by an ip injection of sodium pentobarbitol (65 mg/kg) to maintain anesthesia for another hour. A second capsaicin injection was administered 2 d later following the same protocol. One week after the second injection, mice were treated ip with 100 µl of either saline, Ex4 (0.06 µg), or PYY3–36NH2 (3 µg) alone or in combination, and FI was measured as described above. Efficiency of the capsaicin pretreatment was verified immediately before euthanasia by the corneal chemosensory reflex test, which consists of monitoring the wiping reflex after ocular administration of a drop of 0.1% NH4OH solution (40).
FI was also measured, as above, in mice injected ip with 100 µl of either saline or the GLP-1R antagonist, Ex49–39 (3, 4) (5 µg), alone or in combination with Ex4 (0.06 µg) or PYY3–36NH2 (3 µg). A second set of mice was administered ip 100 µl of either vehicle (50% DMSO) or the NPY Y2-R antagonist, BIIE0246 (42) (50 µg) alone or in combination with Ex4 (0.06 µg) or PYY3–36NH2 (3 µg), and FI was measured as previously described.
Gastric emptying
Mice were housed in separate cages and were food deprived for 16–18 h with free access to water. At t = 0 h animals were given free access to preweighed standard chow for 1 h, and then were injected ip with 100 µl of either saline, Ex4 (0.06 µg), or PYY3–36NH2 (3 µg) alone or in combination. They were deprived of food for 3 h after ip administration and then euthanized. To determine the amount of food remaining in the stomach after the 3-h postinjection period, the stomach was excised at the pylorus and cardia, and the contents were collected, frozen, lyophilized overnight, and weighed. Total FI during the 1 h feeding period was determined by measuring the difference between the preweighed standard chow and the weight of chow and spill. Gastric emptying (%) was calculated as: [1 – (dry weight of food recovered from the stomach/total FI)] x 100 (40).
Behavioral studies
Locomotor activity.
Mice were fasted for 16–18 h before the start of the study and then injected ip with 100 µl of either saline, Ex4 (0.06 or 3 µg), or PYY3–36NH2 (3 µg) alone or in combination (Ex4, 0.06 µg and PYY3–36NH2, 3 µg). Locomotor activity was monitored for 1 h using an Opto-Max system (Columbus Instruments, Columbus, OH).
Conditioned taste aversion (CTA).
To accustom mice to a water deprivation schedule, animals were allowed access to two water bottles (50 ml each) for 1 h/d (1000–1100 h) for 2 d. This was followed by Conditioning Day 1 in which the water was replaced with two bottles (50 ml each) of either cherry or grape Kool-Aid ["Flavor 1" (0.3% Kool-Aid with 1% saccharin)] for 1 h, and mice were then injected ip with 100 µl of saline. Animals were subsequently given 1 d of normal water access (e.g. 1 h/d) as a Rest Day. On Conditioning Day 2, mice received the alternative flavor (two bottles of "Flavor 2"; grape or cherry, respectively) in a counter-balanced manner for 1 h and were then injected with 100 µl of either saline, Ex4 (0.06 or 3 µg), or PYY3–36NH2 (3 µg) alone or in combination (Ex4, 0.06 µg and PYY3–36NH2, 3 µg). This was followed by a Rest Day, and this procedure was then repeated and followed by two Rest Days. On the Test Day, mice were given access to one preweighed bottle of each flavor, and fluid intake was determined as the change in weight after 24 h. CTA was determined as a "Preference Ratio" [(intake of treatment-paired flavor/total intake) x 100%] (43).
Chronic studies
One day before the start of the study, mice were individually housed and body weights were measured and normalized for each treatment group. Mice were weighed between 0900 and 1000 h and injected ip (10 µl/g of mouse) at 1000 and 1800 h for 14 d with either saline, Ex4 (0.06 µg), or PYY3–36NH2 (3 µg) alone or in combination, and were then placed on a diet containing 45% kcal as fat (no. D12451; Research Diet, North Brunswick, NJ) to mimic a typical high-fat diet consumed by humans. Body weight was determined daily at 0900–1000 h, and 8 h FI (1000–1800 h) was measured in fed mice on d 1, 3, 5, 7, 9, 11, and 13, as described above. Magnetic resonance imaging was performed on d 15 to analyze whole body composition (fat and lean mass; EchoMRI, Echo Medical Systems, Houston, TX).
Data analysis
All data are expressed as mean ± SEM. Statistical comparisons between experimental groups were assessed by one- or two-way ANOVA, followed by Student’s t tests, as appropriate.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
). Mice given 0.06 µg of Ex4 also ate significantly less than controls over 8 h (55 ± 7 to 77 ± 5% of the controls; P < 0.05–0.01), whereas higher doses of Ex4 (0.3 and 3 µg) caused a significant suppression of FI over 24 h (Ex4 at 0.3 µg, 28 ± 21 to 63 ± 6%; Ex4 at 3 µg, 17 ± 4 to 65 ± 5% of controls; P < 0.001). Although Ex4 at the higher doses (0.3 and 3 µg) induced a profound inhibition of FI, observation of these animals postinjection indicated that these doses of Ex4 caused abnormal behavioral characteristics (i.e. decreased activity). Unlike Ex4, peripherally administered PYY3–36NH2 was only effective at producing anorexigenic effects at the two highest doses tested (0.3 and 3 µg; Fig. 1B). Mice injected with 0.3 µg ate significantly less than controls from 1–4 h (74 ± 6 to 77 ± 5% of controls; P < 0.05–0.01), whereas 3 µg of PYY3–36NH2 induced a significant decrease in FI from 2–4 h (75 ± 5 to 77 ± 3% of controls; P < 0.05).
|
). However, when given in combination, these peptides significantly decreased FI by 31 ± 3 to 67 ± 3% (P < 0.001) over 8 h. Furthermore, the combination of Ex4 and PYY3–36NH2 had a significantly greater effect than either Ex4 or PYY3–36NH2 alone at 1–8 h (P < 0.001). The decrease in FI produced by the combination was greater than the sum of the individual effects produced by Ex4 and PYY3–36NH2 alone (P < 0.001 over the first 8 h), and two-way ANOVA demonstrated a significant interaction between Ex4 and PYY3–36NH2 at 2–4 h (P < 0.05), indicating synergistic effects of these peptides. Because the effects produced by Ex4 (at 0.06 µg) or PYY3–36NH2 (at 3 µg) either alone or in combination lasted for a maximum of 8 h, all subsequent studies were examined at these doses over an 8-h period only.
To determine whether Ex4 and/or PYY3–36NH2 produce their anorexigenic effects through a neural mechanism, mice were pretreated with vehicle or capsaicin to ablate C-type neural fibers (44). At least 1 wk after the last capsaicin treatment, FI was measured in fasted mice after systemic administration of saline, Ex4, or PYY3–36NH2 alone or in combination. Capsaicin completely abrogated the anorexigenic effect of Ex4 at 1–8 h (P < 0.05) but had no effect on the suppression of FI produced by PYY3–36NH2 alone or in combination with Ex4 (Fig. 2). These results suggest that Ex4 and PYY3–36NH2 exert their inhibitory effects through different mechanisms, with only Ex4 requiring sensory afferent pathways.
|
]. Ex49–39 partially blocked the inhibitory effect of Ex4 (P < 0.05) but had no effect on the suppression of FI produced by PYY3–36NH2. Alternatively, to determine whether Ex4 requires a functional Y2-R to decrease appetite, FI was measured in fasted mice that were systemically administered with vehicle or the specific Y2-R antagonist, BIIE0246, alone or in combination with Ex4 or PYY3–36NH2. The appropriate dose of BIIE0246 was determined in pilot studies (data not shown). Treatment of fasted mice with BIIE0246 completely abrogated the effects of PYY3–36NH2 on FI (P < 0.001), but did not prevent the inhibitory effects produced by Ex4 (Fig. 3B). When taken together, these studies provide further evidence that Ex4 and PYY3–36NH2 reduce appetite through independent pathways.
|
). Mice injected with either Ex4 or PYY3–36NH2 (0.06 and 3 µg, respectively) displayed a small but significant decrease in the rate of gastric emptying (by 6 ± 2 and 8 ± 2% of controls, respectively; P < 0.01–0.001), whereas the combination of peptides induced an even greater decrease (by 19 ± 3% of controls; P < 0.001). However, two-way ANOVA did not indicate a significant interaction between the peptides, suggesting that Ex4 and PYY3–36NH2 produced an additive rather than a synergistic effect on gastric emptying.
|
). However, a significant reduction in activity was observed in mice injected with the high dose of Ex4 (3 µg) compared with the vehicle-treated mice (P < 0.001; positive control). Similarly, low doses of Ex4 and/or PYY3–36NH2 had no effect on CTA. However, aversion was induced in mice treated with Ex4 at 3 µg (P < 0.001; positive control) (Fig. 4C). When taken together, these findings indicate that the suppression of appetite produced by Ex4 and/or PYY3–36NH2 may be partially attributed to delayed gastric emptying, but are not associated with significant behavioral changes.
Finally, to determine whether the acute effects of Ex4 and/or PYY3–36NH2 on FI are sustained, mice were placed on a high-fat diet and peripherally injected twice a day with saline, Ex4, or PYY3–36NH2 alone or in combination for 14 d. Body weight and 8-h FI were measured every 24 and 48 h, respectively. Chronic administration of Ex4 (0.06 µg) or PYY3–36NH2 (3 µg) alone had no effect on 8-h FI compared with vehicle-treated animals. However, Ex4 and PYY3–36NH2 in combination significantly decreased 8-h FI compared with mice given Ex4 or PYY3–36NH2 alone (by 30 ± 7 to 44 ± 4%) on d 5, 9, 11, and 13 (P < 0.01–0.001) (Fig. 5A). Two-way ANOVA indicated a significant interaction between these peptides on d 1, 5, 7, 9, and 11 (P < 0.05–0.01), suggesting that the synergistic effect of Ex4 and PYY3–36NH2 to suppress 8-h FI was not lost in the chronic setting. However, despite the effects on FI, there was no difference in body weight gain between the animals treated with Ex4 and/or PYY3–36NH2 compared with controls (Fig. 5B). Body composition analysis further verified that there was no difference between the different groups of mice (data not shown).
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Fasted control mice in this study ate approximately 6–7.5 g or 0.3 g per gram of body weight over a 24-h period, which is consistent with the results of other studies (47). The anorexigenic effects of peripheral Ex4 and PYY3–36NH2 on fasted mice were found to be synergistic when administered acutely, by up to 67% for an 8-h period. This interaction was not lost during chronic studies, indicating the absence of tachyphylaxis to the acute effects of Ex4 and PYY3–36NH2 on FI. Synergistic interactions between a number of other anorexigenic hormones have been reported. CCK is a short-term satiety factor that is released from the gut after nutrient ingestion, whereas leptin is a long-term regulator of appetite and body fat stores, the levels of which are proportional to fat mass. Coadministration of leptin and CCK-8 synergistically decreases FI in rodents both acutely and chronically (40, 48). Similarly, Bhavsar et al. (41) examined the interaction of CCK with another regulator of appetite, amylin, which is cosecreted with insulin from pancreatic B cells in response to nutrient stimuli. Systemic coadministration of these hormones in mice acutely reduced FI by up to 91%, an inhibition that was greater than that produced by amylin or CCK alone. Because secretion of GLP-1, PYY, and CCK, as well as of another intestinal satiety hormone, oxyntomodulin, is enhanced in the fed state, these findings suggest that the total gut satiety response to nutrient ingestion is mediated through the actions of multiple hormones acting in an integrated fashion.
The present study has also demonstrated that Ex4 and PYY3–36NH2 produce their anorexigenic effects through independent mechanisms. Specifically, Ex4 decreased FI through a sensory neural mechanism, whereas PYY3–36NH2 did not appear to require such pathways. Furthermore, the actions of these peptides were produced through activation of the GLP-1R and Y2-R, respectively, as demonstrated through the use of receptor-specific antagonists. Recently, mRNA transcripts for the GLP-1 and Y2-receptors have been localized in the rat nodose ganglion, which contains the cell bodies of afferent vagal neurons (35, 36). Systemic pretreatment of mice with capsaicin causes selective degeneration of small diameter unmyelinated sensory neurons (49), including the nodose ganglion (50) and the vagus nerve (36). Interestingly, capsaicin blocked the inhibition of appetite by Ex4, but had no such effect on PYY3–36NH2-induced satiety. It is acknowledged that there are some side-effects associated with the use of capsaicin, including effects to decrease blood pressure and body temperature, which are thought to be induced via peripheral actions (44). However, like the GLP-1R and Y2-R, capsaicin receptors are also centrally located in the NTS and AP in rats (52), areas that relay signals to the hypothalamus to regulate FI. It is currently unclear whether peripherally administered capsaicin affects these central regions but, based on the results of the present study, capsaicin treatment did not alter FI in control mice, suggesting that its effects on Ex4-induced FI were mediated via ablation of peripheral sensory afferent signals. Consistent with this notion, a number of studies have demonstrated that although peripheral Ex4 can induce c-fos in the AP and NTS (45), Ex4 can also directly activate vagal fibers (53). Other biological actions of GLP-1, such as the stimulation of insulin secretion, are also proposed to require a sensory afferent neural pathway, because a low dose of GLP-1 does not augment the insulin response to glucose in capsaicin-pretreated mice (54). Furthermore, capsaicin treatment completely abrogated the effects of CCK and leptin on FI (40), indicating that these peptides produce at least some of their anorexigenic actions through similar peripheral neural mechanisms. Nonetheless, these findings differ from a report demonstrating that PYY3–36NH2 acts through the vagus to inhibit FI in rats (36). These contradictory results may occur consequent to species differences in the expression of the Y2-R in the nodose ganglion, as c-fos immunoreactivity is not observed in the NTS after peripheral administration of PYY3–36NH2 in mice (55), but is induced in rats treated systemically with PYY3–36NH2 (36).
The possibility that Ex4 and/or PYY3–36NH2 may suppress FI by acting directly in the brain must be considered, as both of these peptides have been demonstrated to cross the BBB (38, 39). Baggio et al. (47) have shown that peripheral administration of Albugon, a GLP-1-albumin recombinant protein, suppresses FI in mice, thereby demonstrating that the satiating effects of GLP-1 can be mediated through the periphery. Furthermore, a long-acting analog of GLP-1 suppresses FI when injected peripherally into monosodium glutamate-treated rats that cannot respond to central administration of the peptide (57). Therefore, when taken together, these findings suggest that effects of Ex4 on FI in the present study are mediated peripherally. Nonetheless, it remains possible that some of the effects of higher doses of Ex4 on FI may be exerted through direct effects on GLP-1R expressed in the brain. Similarly, although numerous studies have found that PYY3–36NH2 is effective at decreasing FI when given systemically (25, 26, 27, 28, 29, 30), Nonaka et al. (39) have reported that PYY3–36NH2 crosses the BBB by a nonsaturable process, perhaps thereby reaching the Y2-R in the arcuate nucleus (58). Because pretreatment with capsaicin did not prevent the effects of PYY3–36NH2 on feeding, it cannot be excluded that the actions of PYY3–36NH2 on satiety are mediated through direct modulation of Y2-receptors in the brain.
GLP-1 and PYY are cosecreted from the L cells of the distal colon along with other gut peptides that have been found to decrease FI, including oxyntomodulin (45, 46). Interestingly, previous studies have shown that oxyntomodulin requires the GLP-1R signaling pathway to produce its anorexigenic effects (45, 46). Similarly, administration of the CCK-A receptor antagonist, devazepide, with CCK and leptin completely prevents the inhibitory effects of CCK and leptin coinjection (40). However, the effects of Ex4 and PYY3–36NH2 on FI have now been demonstrated to be mediated independently, because the GLP-1R antagonist, Ex49–39 did not block the inhibitory effects induced by PYY3–36NH2, whereas the Y2-R antagonist BIIE0246 was unable to prevent the effects of Ex4.
The present study suggests that the inhibition of FI produced by Ex4 and PYY3–36NH2 may be partially attributed to decreased gastric emptying. This is consistent with previous reports that peripheral administration of Ex4 or PYY3–36NH2 alone in rodents and humans delays gastric emptying (9, 47, 59, 60), possibly through a vagal pathway. The present study also demonstrated that coadministration of Ex4 and PYY3–36NH2 induced an even greater inhibition of gastric emptying than Ex4 or PYY3–36NH2 alone. However, unlike their effects on FI, the combined effects of these peptides on gastric emptying were additive rather than synergistic. Furthermore, coinjection of CCK and leptin reduced FI but had no effect on gastric emptying (40). Hence, although gastric distension may induce satiety (61), the synergistic effects of Ex4 and PYY3–36NH2 on FI may be produced through alternative mechanisms. One possible mechanism may be at the level of the arcuate nucleus, where signals from a variety of different peripheral and central inputs are integrated to modulate the balance between orexigenic (e.g. NPY and agouti-related protein) and anorexigenic (e.g. 
-MSH) neuropeptides (33, 34). Further studies will clearly be necessary to elucidate the specific neural mechanisms by which the combination of Ex4 and PYY3–36NH2 produce their synergistic effects to regulate ingestive behavior.
To determine whether the reduction of food consumption was secondary to nonspecific behavioral effects of the treatments in the present study, both taste aversion and locomotor activity were assessed. The present study demonstrated that mice treated with doses of Ex4 and/or PYY3–36NH2 sufficient to decrease FI, did not display either taste aversion or altered motor activity; however, a very high dose of Ex4 caused a significant taste aversion and decreased total activity. Although adverse effects of Ex4 have not been extensively examined in rodents, considerable evidence exists for such effects of GLP-1. Central administration of GLP-1 in the lateral and third ventricle, but not in the PVN, induces taste aversion in rats (62, 63, 64). Furthermore, the mechanisms underlying taste aversion appear to be species-specific, as central administration of the toxin LiCl to rats produces CTA in a GLP-1-dependent manner; however, mice lacking the GLP-1R still display taste aversion after administration of LiCl (43). In addition, Ex4 has been shown to produce noxious responses in humans leading to nausea and vomiting (65). Previous studies have also demonstrated that peripheral administration of high doses of Ex4 caused a decrease in activity in rats (66), although central administration of GLP-1 in rodents had no such effect (5, 64). Finally, Tschop et al. (67) did not find an effect of PYY3–36NH2 on taste aversion after either central or peripheral administration, nor was there any significant effect of peripheral PYY3–36NH2 on locomotion in rodents. Thus, the adverse side effects of these particular peptides are both species- and dose-dependent and rely, at least in part, on the route of administration. However, based on the results of the present study, it may be inferred that Ex4 (at 0.06 µg) and PYY3–36NH2 (at 3 µg) most likely exerted specific effects on ingestive behavior, rather than inducing behavioral abnormalities.
One unexpected observation in these studies was the finding that the GLP-1R antagonist, Ex49–39 significantly reduced FI at the high dose (50 µg) (data not shown). These findings indicate that Ex49–39 may be a partial agonist of the GLP-1R, consistent with previous studies that examined cAMP responses to Ex49–39 in vitro and FI in rats after peripheral administration of Ex49–39 (3, 66). This may also explain the observation that Ex49–39 was unable to completely block the effects of Ex4 on FI, even when given at 83-fold greater amounts relative to Ex4 (5.0 vs. 0.06 µg, respectively).
Although Ex4 and PYY3–36NH2 decreased 8-h FI, this did not translate into decreased body weight in chronic studies on mice eating a high-fat diet. Chronic peripheral administration of a long-acting analog of GLP-1 previously has been demonstrated to reduce both FI and body weight in nonobese, nondiabetic rats (57). However, the dose of peptide necessary to induce body weight loss was 200 µg/kg, whereas Ex4 was administered at approximately 3 µg/kg in the present study, a dose that was selected to minimize the possibility of side-effects such as nausea contributing to the reductions in FI. Furthermore, although chronic peripheral administration of PYY3–36NH2 at a dose of 50 µg/kg decreases FI and body weight in normal rats (25), 2-fold higher amounts of PYY3–36NH2 suppress FI but do not reduce body weight in chronic studies in wild-type mice (51). These latter findings are consistent with the results of the present study, in which approximately 170 µg/kg PYY3–36NH2 was administered chronically to mice. Hence, in chronic feeding studies, both the dose of peptide being tested and the species being used may influence the ultimate effect on body weight. Finally, the injection schedule used in such studies (1000 and 1800 h in the present study) may contribute to any lack of effect on body weight, as animals are known to adaptively modulate their FI to maintain long-term body weight (56).
In conclusion, the present study has demonstrated that Ex4 and PYY3–36NH2 (at the doses evaluated) act synergistically to reduce appetite without producing adverse behavioral effects. These peptides regulate FI through independent mechanisms, whereby Ex4 acts via a sensory afferent pathway involving the GLP-1R, but not the Y2-R, and PYY3–36NH2 acts through an alternative pathway involving the Y2-R, but one that is independent of the GLP-1R. Although high doses of Ex4 are known to cause nausea and vomiting in humans, lower doses of Ex4 alone or in combination with PYY3–36NH2 exerted only a small effect on gastric emptying, and neither peptide exhibited adverse behavioral actions. Therefore these findings suggest that the anorexigenic effects of low doses of Ex4 may be enhanced by coadministration of PYY3–36NH2, without induction of major side effects. Collectively, this information will serve as basis for the development of a more effective treatment for obesity.
|
Acknowledgments |
|---|
|
Footnotes |
|---|
First Published Online June 2, 2005
Abbreviations: AP, Area postrema; BBB, blood-brain barrier; CCK, cholecystokinin; CTA, conditioned taste aversion; DMSO, dimethyl sulfoxide; Ex4, exendin-41–39; Ex49–39, exendin-49–39; FI, food intake; GLP-1, glucagon-like peptide-17–36NH2; GLP-1R, GLP-1-receptor; NPY, neuropeptide Y; NTS, nucleus tractus solitarus; PYY3–36NH2, peptide YY3–36NH2; Y2-R, Y2-receptor.
Received April 20, 2005.
Accepted for publication May 23, 2005.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
This article has been cited by other articles:
 |
|
 |
|
  D. L. Williams Minireview: Finding the Sweet Spot: Peripheral Versus Central Glucagon-Like Peptide 1 Action in Feeding and Glucose Homeostasis Endocrinology, July 1, 2009; 150(7): 2997 - 3001. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Lauffer, R. Iakoubov, and P. L. Brubaker GPR119 Is Essential for Oleoylethanolamide-Induced Glucagon-Like Peptide-1 Secretion From the Intestinal Enteroendocrine L-Cell Diabetes, May 1, 2009; 58(5): 1058 - 1066. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Williams, D. G. Baskin, and M. W. Schwartz Evidence that Intestinal Glucagon-Like Peptide-1 Plays a Physiological Role in Satiety Endocrinology, April 1, 2009; 150(4): 1680 - 1687. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. B. Ruttimann, M. Arnold, J. J. Hillebrand, N. Geary, and W. Langhans Intrameal Hepatic Portal and Intraperitoneal Infusions of Glucagon-Like Peptide-1 Reduce Spontaneous Meal Size in the Rat via Different Mechanisms Endocrinology, March 1, 2009; 150(3): 1174 - 1181. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Karra, K. Chandarana, and R. L. Batterham The role of peptide YY in appetite regulation and obesity J. Physiol., January 1, 2009; 587(1): 19 - 25. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Islam, N. Zhang, P. Wang, H. Li, P. L. Brubaker, H. Y. Gaisano, Q. Wang, and T. Jin Epac is involved in cAMP-stimulated proglucagon expression and hormone production but not hormone secretion in pancreatic {alpha}- and intestinal L-cell lines Am J Physiol Endocrinol Metab, January 1, 2009; 296(1): E174 - E181. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Kim and J. M. Egan The Role of Incretins in Glucose Homeostasis and Diabetes Treatment Pharmacol. Rev., December 1, 2008; 60(4): 470 - 512. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Hayes, K. P. Skibicka, and H. J. Grill Caudal Brainstem Processing Is Sufficient for Behavioral, Sympathetic, and Parasympathetic Responses Driven by Peripheral and Hindbrain Glucagon-Like-Peptide-1 Receptor Stimulation Endocrinology, August 1, 2008; 149(8): 4059 - 4068. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R P Vincent and C W le Roux The satiety hormone peptide YY as a regulator of appetite J. Clin. Pathol., May 1, 2008; 61(5): 548 - 552. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Yi, J. Sun, G. E. Lim, I. G. Fantus, P. L. Brubaker, and T. Jin Cross Talk between the Insulin and Wnt Signaling Pathways: Evidence from Intestinal Endocrine L Cells Endocrinology, May 1, 2008; 149(5): 2341 - 2351. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. C. Parkinson, W. S. Dhillo, C. J. Small, O. B. Chaudhri, G. A. Bewick, I. Pritchard, S. Moore, M. A. Ghatei, and S. R. Bloom PYY3-36 injection in mice produces an acute anorexigenic effect followed by a delayed orexigenic effect not observed with other anorexigenic gut hormones Am J Physiol Endocrinol Metab, April 1, 2008; 294(4): E698 - E708. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. G. Kumar, L. O. Byerley, J. Volaufova, D. J. Drucker, G. A. Churchill, R. Li, B. York, A. Zuberi, and B. K. S. Richards Genetic variation in Glp1r expression influences the rate of gastric emptying in mice Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2008; 294(2): R362 - R371. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Hao, C. Sternini, and H. E. Raybould Role of CCK1 and Y2 receptors in activation of hindbrain neurons induced by intragastric administration of bitter taste receptor ligands Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2008; 294(1): R33 - R38. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Roth, T. Coffey, C. M. Jodka, H. Maier, J. R. Athanacio, C. M. Mack, C. Weyer, and D. G. Parkes Combination Therapy with Amylin and Peptide YY[3 36] in Obese Rodents: Anorexigenic Synergy and Weight Loss Additivity Endocrinology, December 1, 2007; 148(12): 6054 - 6061. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. L. Whited, P. Tso, and H. E. Raybould Involvement of Apolipoprotein A-IV and Cholecystokinin1 Receptors in Exogenous Peptide YY3 36-Induced Stimulation of Intestinal Feedback Endocrinology, October 1, 2007; 148(10): 4695 - 4703. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A. Scott and T. H. Moran The GLP-1 agonist exendin-4 reduces food intake in nonhuman primates through changes in meal size Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2007; 293(3): R983 - R987. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. C. McDonagh, J. Lee, A. Izzo, and P. L. Brubaker Role of glial cell-line derived neurotropic factor family receptor {alpha}2 in the actions of the glucagon-like peptides on the murine intestine Am J Physiol Gastrointest Liver Physiol, August 1, 2007; 293(2): G461 - G468. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. K. Chelikani, A. C. Haver, and R. D. Reidelberger Intermittent intraperitoneal infusion of peptide YY(3-36) reduces daily food intake and adiposity in obese rats Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2007; 293(1): R39 - R46. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. L. Sowden, D. J. Drucker, D. Weinshenker, and S. J. Swoap Oxyntomodulin increases intrinsic heart rate in mice independent of the glucagon-like peptide-1 receptor Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2007; 292(2): R962 - R970. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. G. Murphy, W. S. Dhillo, and S. R. Bloom Gut Peptides in the Regulation of Food Intake and Energy Homeostasis Endocr. Rev., December 1, 2006; 27(7): 719 - 727. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Williams, D. G. Baskin, and M. W. Schwartz Leptin Regulation of the Anorexic Response to Glucagon-Like Peptide-1 Receptor Stimulation Diabetes, December 1, 2006; 55(12): 3387 - 3393. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K J Oliveira, G S M Paula, R H Costa-e-Sousa, L L Souza, D C Moraes, F H Curty, and C C Pazos-Moura Peptide YY (PYY)3-36 modulates thyrotropin secretion in rats. J. Endocrinol., November 1, 2006; 191(2): 459 - 463. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Rozengurt, S. V. Wu, M. C. Chen, C. Huang, C. Sternini, and E. Rozengurt Colocalization of the {alpha}-subunit of gustducin with PYY and GLP-1 in L cells of human colon Am J Physiol Gastrointest Liver Physiol, November 1, 2006; 291(5): G792 - G802. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Rozengurt Taste Receptors in the Gastrointestinal Tract. I. Bitter taste receptors and {alpha}-gustducin in the mammalian gut Am J Physiol Gastrointest Liver Physiol, August 1, 2006; 291(2): G171 - G177. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Chaudhri, C. Small, and S. Bloom Gastrointestinal hormones regulating appetite Phil Trans R Soc B, July 29, 2006; 361(1471): 1187 - 1209. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. T. Gunnarsson, M. S. Winzell, C. F. Deacon, M. O. Larsen, K. Jelic, R. D. Carr, and B. Ahren Glucose-Induced Incretin Hormone Release and Inactivation Are Differently Modulated by Oral Fat and Protein in Mice Endocrinology, July 1, 2006; 147(7): 3173 - 3180. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. B. Chaudhri, B. C. T. Field, and S. R. Bloom From gut to mind--hormonal satiety signals and anorexia nervosa. J. Clin. Endocrinol. Metab., March 1, 2006; 91(3): 797 - 798. [Full Text] [PDF]
|
|
|
|
|
|
N. M. Neary, C. J. Small, M. R. Druce, A. J. Park, S. M. Ellis, N. M. Semjonous, C. L. Dakin, K. Filipsson, F. Wang, A. S. Kent, et al. Peptide YY3-36 and Glucagon-Like Peptide-17-36 Inhibit Food Intake Additively Endocrinology, December 1, 2005; 146(12): 5120 - 5127. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
, n = 6) or Ex4 (0.03 µg 
, n = 6; 0.06 µg 
, n = 9; 0.3 µg 
, n = 5; 3 µg 
, n = 6) (A), with saline (
, P < 0.05; 
, PYY3–36NH2 
, in combination 
). *, P < 0.05; **, P < 0.01 vs. Ex4-treated mice; ##, P < 0.01; ###, P < 0.001 vs. PYY3–36NH2-treated mice.